Efgartigimod in Anti-NMDA Receptor Encephalitis.

计划入组 20 人 · 首次发布于 2026 年 9 月 16 日

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

计划入组 680 人 · 首次发布于 2024 年 3 月 7 日

Efgartigimod for the Treatment of Acute Optic Neuritis

计划入组 20 人 · 首次发布于 2024 年 6 月 12 日

Efgartigimod/Hyaluronidase

Efgartigimod Alfa(Vyvgart, Vyvgart Hytrulo)

Rx

Efgartigimod

Alfa Wassermann SpA

Italy

Hospital General Puyo

Ecuador

CAIRNS AND HINTERLAND HOSPITAL AND HEALTH SERVICE

Australia

VYVDURA Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

FDA Grants Accelerated Approval to Krazati Plus Cetuximab for KRAS G12C-Mutated Colorectal Cancer

VYVGART Hytrulo Approved by FDA as First FcRn Blocker for CIDP Treatment